Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 1.19TCr 1.02TCr 956.9Cr 875.93Cr 1.64TCr 1,14200Cr 1.67TCr 11TCr 4.41TCr 57TCr 4.48TCr 4.39TCr 1,89800Cr P/E 2026 *
-81.8x
P/E 2027 * 82.1x
Enterprise Value 1.14TCr 977.75Cr 914.86Cr 837.44Cr 1.57TCr 1,09200Cr 1.59TCr 11TCr 4.22TCr 55TCr 4.29TCr 4.19TCr 1,81500Cr EV / Sales 2026 *
7.48x
EV / Sales 2027 * 5.13x
Free-Float
94.13%
Yield 2026 *
-
Yield 2027 * -
1 day-0.45%
1 week+1.81%
Current month+10.58%
1 month-3.89%
3 months-0.10%
6 months+18.79%
Current year-11.26%
1 week 506.84
Extreme 506.845
542.78
1 month 447.01
Extreme 447.01
566.18
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 9.2
Extreme 9.2
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

General Counsel

-664 0.0029%
15/08/26 Free

Director

1,725 0.0075%
20/07/26 Sell

Chief Executive Officer

-2,500 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
-0.45%+1.81%+24.61%+185.67% 1.19TCr
-3.00%+2.27%+73.26%+109.90% 7.21TCr
+1.90%+23.53%+59.48%+94.82% 6.59TCr
+5.12%+25.22%+5.13%-5.86% 2.93TCr
+0.55%+1.64%-4.63%+480.92% 2.75TCr
+2.74%+12.98%+54.92%+25.77% 2.67TCr
+0.47%+6.12%+37.01%-15.31% 2.01TCr
+1.82%-6.67%+251.36%+388.91% 1.82TCr
+0.94%+3.36%+15.30%+548.19% 1.64TCr
+0.73%+5.54%+39.99%+151.77% 1.34TCr
Average +1.08%+7.71%+55.64%+196.48% 3.01TCr
Weighted average by Cap. +0.69%+9.18%+56.70%+158.96%

Financials

2026 *2027 *
Net sales 152.63Cr 130.74Cr 122.33Cr 111.98Cr 210.16Cr 15TCr 212.93Cr 1.45TCr 563.63Cr 7.34TCr 573.11Cr 560.64Cr 24TCr 214.49Cr 183.73Cr 171.91Cr 157.37Cr 295.33Cr 21TCr 299.23Cr 2.03TCr 792.06Cr 10TCr 805.38Cr 787.86Cr 34TCr
Net income -18Cr -16Cr -15Cr -13Cr -25Cr -1.76TCr -26Cr -174.11Cr -68Cr -883.74Cr -69Cr -68Cr -2.92TCr 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 28Cr 189.38Cr 74Cr 961.26Cr 75Cr 73Cr 3.18TCr
Net Debt -52Cr -45Cr -42Cr -38Cr -72Cr -5.02TCr -73Cr -496.7Cr -193.7Cr -2.52TCr -196.95Cr -192.67Cr -8.34TCr -94Cr -81Cr -76Cr -69Cr -129.87Cr -9.02TCr -131.59Cr -893.18Cr -348.31Cr -4.53TCr -354.17Cr -346.46Cr -15TCr
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
21/26/21 $516.74 -0.45% 1,79,832
20/26/20 $519.09 -3.90% 2,64,483
19/26/19 $540.16 +3.01% 2,21,134
18/26/18 $524.37 -0.10% 3,56,197
17/26/17 $524.87 +3.41% 3,07,441
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
516.74USD
Average target price
678.06USD
Spread / Average Target
+31.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock